The Patent Finder

Terms ending in 2030

Pharmacyclics, Inc.

Every in-force patent on Pharmacyclics, Inc.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,883,803Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Grace period ended Nov 11, 2026 · lapse expected
 · Low confidence
Pharmacyclics LLCGrace period ended Nov 11, 2026
lapse expected
Low confidence
US 8,466,193Selective Inhibitors of Histone Deacetylase
In force
 · High confidence
Pharmacyclics LLCIn forceHigh confidence
US 9,403,032Formulations of Histone Deacetylase Inhibitor and Uses Therof
In force
 · Medium confidence
Pharmacyclics LLCIn forceMedium confidence
US 8,552,046Manufacture, Compositions and Uses of Coagulation Factor Viia Modulator
In force
 · High confidence
Pharmacyclics LLCIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited